Pharmaceutical use The half-life of is long enough that labelling synthesis of the
radiopharmaceutical and scintigraphic measurements can be performed without significant loss of radioactivity. Other methods of administration include intraperitoneal, intramuscular, subcutaneous, as well as orally. The behavior of the ion is essentially the same, with small differences due to the difference in rate of absorption, regardless of the method of administration.
Synthesis of 99mTcO4− radiopharmaceuticals is advantageous for the synthesis of a variety of radiopharmaceuticals because Tc can adopt a number of oxidation states. It has also been used historically to evaluate for
testicular torsion, although
ultrasound is more commonly used in current practice, as it does not deliver a radiation dose to the
testes. It is also used in labeling of autologous
red blood cells for
MUGA scans to evaluate left ventricular cardiac function, localization of gastrointestinal bleeding prior to embolization or surgical management, and in damaged red blood cells to detect ectopic
splenic tissue. It is actively accumulated and secreted by the mucoid cells of the gastric mucosa, and therefore, technetate(VII) radiolabeled with technetium-99m is injected into the body when looking for ectopic gastric tissue as is found in a
Meckel's diverticulum with Meckel's scans.
Non-radioactive uses All technetium salts are mildly radioactive, but some of them have explored use of the element for its chemical properties. In these uses, its radioactivity is incidental, and generally the least radioactive (longest-lived) isotopes of Tc are used. In particular,
99Tc (half-life 211,000 years) is used in corrosion research, because it is the decay product of the easily obtained commercial 99mTc isotope. ==See also==